Despite a rich history in the discovery of new treatments and vaccines, Europe is going backwards when it comes to medical innovation. As a region, we have been falling behind global competitors in R&D and manufacturing, with lower investment, fewer clinical trials and longer approval times for new medicines for the last 25 years.
We have one shot at making Europe an innovation hub. Failure is not an option.
Read more
EFPIA suggests reasons for the drop in PRIME applications, including the rejection rate.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.